Trusted News Discovery Since 2008
{{/content}}
United States: Biocon Settles With Bayer And Regeneron, Securing Canada Market Entry Date For Aflibercept Biosimilar - Goodwin Procter LLP
Credit: Mondaq- Published on March 15, 2024
On March 4, Biocon Biologics Ltd. announced it has signed a settlement agreement with Bayer Inc. and Regeneron Pharmaceuticals, Inc. regarding YESAFILI, Biocon's proposed biosimilar to EYLEA.
You are here
Related news from verified sources
On February 29, Biocon Biologics Ltd announced that it signed a settlement and license agreement with Janssen Biotech Inc. and Johnson & Johnson ("J&J")...
on March 15, 2024 • Mondaq